Ontology type: schema:ScholarlyArticle
2019-12
AUTHORSIrina Velikyan, Torsten Haack, Martin Bossart, Andreas Evers, Iina Laitinen, Philip Larsen, Oliver Plettenburg, Lars Johansson, Stefan Pierrou, Michael Wagner, Olof Eriksson
ABSTRACTThe glucagon receptor (GCGR) is emerging as an important target in anti-diabetic therapy, especially as part of the pharmacology of dual glucagon-like peptide-1/glucagon (GLP-1/GCG) receptor agonists. However, currently, there are no suitable biomarkers that reliably demonstrate GCG receptor target engagement. METHODS: Two potent GCG receptor peptide agonists, S01-GCG and S02-GCG, were labeled with positron emission tomography (PET) radionuclide gallium-68. The GCG receptor binding affinity and specificity of the resulting radiopharmaceuticals [68Ga]Ga-DO3A-S01-GCG and [68Ga]Ga-DO3A-S02-GCG were evaluated in HEK-293 cells overexpressing the human GCG receptor and on frozen hepatic sections from human, non-human primate, and rat. In in vivo biodistribution, binding specificity and dosimetry were assessed in rat. RESULTS: [68Ga]Ga-DO3A-S01-GCG in particular demonstrated GCG receptor-mediated binding in cells and liver tissue with affinity in the nanomolar range required for imaging. [68Ga]Ga-DO3A-S01-GCG binding was not blocked by co-incubation of a GLP-1 agonist. In vivo binding in rat liver was GCG receptor specific with low non-specific binding throughout the body. Moreover, the extrapolated human effective doses, predicted from rat biodistribution data, allow for repeated PET imaging potentially also in combination with GLP-1R radiopharmaceuticals. CONCLUSION: [68Ga]Ga-DO3A-S01-GCG thus constitutes a first-in-class PET tracer targeting the GCG receptor, with suitable properties for clinical development. This tool has potential to provide direct quantitative evidence of GCG receptor occupancy in humans. More... »
PAGES17
http://scigraph.springernature.com/pub.10.1186/s13550-019-0482-0
DOIhttp://dx.doi.org/10.1186/s13550-019-0482-0
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1112168851
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/30771019
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Pharmacology and Pharmaceutical Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Uppsala University",
"id": "https://www.grid.ac/institutes/grid.8993.b",
"name": [
"PET Centre, Centre for Medical Imaging, Uppsala University Hospital, Uppsala, Sweden",
"Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden"
],
"type": "Organization"
},
"familyName": "Velikyan",
"givenName": "Irina",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi (Germany)",
"id": "https://www.grid.ac/institutes/grid.420214.1",
"name": [
"Sanofi-Aventis Deutschland GmbH, Industriepark H\u00f6chst, 65926, Frankfurt am Main, Germany"
],
"type": "Organization"
},
"familyName": "Haack",
"givenName": "Torsten",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi (Germany)",
"id": "https://www.grid.ac/institutes/grid.420214.1",
"name": [
"Sanofi-Aventis Deutschland GmbH, Industriepark H\u00f6chst, 65926, Frankfurt am Main, Germany"
],
"type": "Organization"
},
"familyName": "Bossart",
"givenName": "Martin",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi (Germany)",
"id": "https://www.grid.ac/institutes/grid.420214.1",
"name": [
"Sanofi-Aventis Deutschland GmbH, Industriepark H\u00f6chst, 65926, Frankfurt am Main, Germany"
],
"type": "Organization"
},
"familyName": "Evers",
"givenName": "Andreas",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi (Germany)",
"id": "https://www.grid.ac/institutes/grid.420214.1",
"name": [
"Sanofi-Aventis Deutschland GmbH, Industriepark H\u00f6chst, 65926, Frankfurt am Main, Germany"
],
"type": "Organization"
},
"familyName": "Laitinen",
"givenName": "Iina",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi (Germany)",
"id": "https://www.grid.ac/institutes/grid.420214.1",
"name": [
"Sanofi-Aventis Deutschland GmbH, Industriepark H\u00f6chst, 65926, Frankfurt am Main, Germany"
],
"type": "Organization"
},
"familyName": "Larsen",
"givenName": "Philip",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Hannover",
"id": "https://www.grid.ac/institutes/grid.9122.8",
"name": [
"Institute of Medicinal Chemistry, Helmholtz Zentrum M\u00fcnchen, German Research Center for Environmental Health (GmbH), Neuherberg, Germany",
"Institute of Organic Chemistry, Leibniz Universit\u00e4t Hannover, Hannover, Germany"
],
"type": "Organization"
},
"familyName": "Plettenburg",
"givenName": "Oliver",
"type": "Person"
},
{
"affiliation": {
"name": [
"Antaros Medical AB, Uppsala Science Park, Dag Hammarskj\u00f6lds V\u00e4g 14B, M\u00f6lndal, SE-751 83, Uppsala, Sweden"
],
"type": "Organization"
},
"familyName": "Johansson",
"givenName": "Lars",
"type": "Person"
},
{
"affiliation": {
"name": [
"Antaros Medical AB, Uppsala Science Park, Dag Hammarskj\u00f6lds V\u00e4g 14B, M\u00f6lndal, SE-751 83, Uppsala, Sweden"
],
"type": "Organization"
},
"familyName": "Pierrou",
"givenName": "Stefan",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi (Germany)",
"id": "https://www.grid.ac/institutes/grid.420214.1",
"name": [
"Sanofi-Aventis Deutschland GmbH, Industriepark H\u00f6chst, 65926, Frankfurt am Main, Germany"
],
"type": "Organization"
},
"familyName": "Wagner",
"givenName": "Michael",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Uppsala University",
"id": "https://www.grid.ac/institutes/grid.8993.b",
"name": [
"Antaros Medical AB, Uppsala Science Park, Dag Hammarskj\u00f6lds V\u00e4g 14B, M\u00f6lndal, SE-751 83, Uppsala, Sweden",
"Science For Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden"
],
"type": "Organization"
},
"familyName": "Eriksson",
"givenName": "Olof",
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.2337/db09-0278",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1000562521"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10967-010-0555-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1001584079",
"https://doi.org/10.1007/s10967-010-0555-z"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10967-010-0555-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1001584079",
"https://doi.org/10.1007/s10967-010-0555-z"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-014-2745-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1002997915",
"https://doi.org/10.1007/s00259-014-2745-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/304368a0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015042332",
"https://doi.org/10.1038/304368a0"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-009-1363-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015567221",
"https://doi.org/10.1007/s00259-009-1363-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00259-009-1363-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015567221",
"https://doi.org/10.1007/s00259-009-1363-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00125-014-3166-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034253462",
"https://doi.org/10.1007/s00125-014-3166-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00125-014-3166-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034253462",
"https://doi.org/10.1007/s00125-014-3166-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nchembio.209",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037064127",
"https://doi.org/10.1038/nchembio.209"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nchembio.209",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037064127",
"https://doi.org/10.1038/nchembio.209"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.2967/jnumed.112.114066",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1041683043"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/bc030078f",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1055153476"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/bc030078f",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1055153476"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1210/jc.2013-3541",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1064294700"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1079103046",
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/acs.jmedchem.7b00174",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1085347683"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00125-017-4354-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1090855737",
"https://doi.org/10.1007/s00125-017-4354-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00125-017-4354-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1090855737",
"https://doi.org/10.1007/s00125-017-4354-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00592-017-1046-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1091514188",
"https://doi.org/10.1007/s00592-017-1046-2"
],
"type": "CreativeWork"
}
],
"datePublished": "2019-12",
"datePublishedReg": "2019-12-01",
"description": "The glucagon receptor (GCGR) is emerging as an important target in anti-diabetic therapy, especially as part of the pharmacology of dual glucagon-like peptide-1/glucagon (GLP-1/GCG) receptor agonists. However, currently, there are no suitable biomarkers that reliably demonstrate GCG receptor target engagement.\nMETHODS: Two potent GCG receptor peptide agonists, S01-GCG and S02-GCG, were labeled with positron emission tomography (PET) radionuclide gallium-68. The GCG receptor binding affinity and specificity of the resulting radiopharmaceuticals [68Ga]Ga-DO3A-S01-GCG and [68Ga]Ga-DO3A-S02-GCG were evaluated in HEK-293 cells overexpressing the human GCG receptor and on frozen hepatic sections from human, non-human primate, and rat. In in vivo biodistribution, binding specificity and dosimetry were assessed in rat.\nRESULTS: [68Ga]Ga-DO3A-S01-GCG in particular demonstrated GCG receptor-mediated binding in cells and liver tissue with affinity in the nanomolar range required for imaging. [68Ga]Ga-DO3A-S01-GCG binding was not blocked by co-incubation of a GLP-1 agonist. In vivo binding in rat liver was GCG receptor specific with low non-specific binding throughout the body. Moreover, the extrapolated human effective doses, predicted from rat biodistribution data, allow for repeated PET imaging potentially also in combination with GLP-1R radiopharmaceuticals.\nCONCLUSION: [68Ga]Ga-DO3A-S01-GCG thus constitutes a first-in-class PET tracer targeting the GCG receptor, with suitable properties for clinical development. This tool has potential to provide direct quantitative evidence of GCG receptor occupancy in humans.",
"genre": "research_article",
"id": "sg:pub.10.1186/s13550-019-0482-0",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1045165",
"issn": [
"2191-219X"
],
"name": "EJNMMI Research",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "9"
}
],
"name": "First-in-class positron emission tomography tracer for the glucagon receptor",
"pagination": "17",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"15725580a4a58a438d85159f00df3f9a3a744c49270f51da0ffea63c17b5ba3e"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"30771019"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"101560946"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s13550-019-0482-0"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1112168851"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s13550-019-0482-0",
"https://app.dimensions.ai/details/publication/pub.1112168851"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T11:18",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000354_0000000354/records_11704_00000002.jsonl",
"type": "ScholarlyArticle",
"url": "https://link.springer.com/10.1186%2Fs13550-019-0482-0"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13550-019-0482-0'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13550-019-0482-0'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13550-019-0482-0'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13550-019-0482-0'
This table displays all metadata directly associated to this object as RDF triples.
190 TRIPLES
21 PREDICATES
43 URIs
21 LITERALS
9 BLANK NODES